Form 4 for PCVX Vaxcyte, Inc.
Accepted 2026-03-18 00:00:00 ET · period of report 2026-03-17 · accession 0001960048-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-18 | 2026-03-17 | PCVX | Cowan Elvia | SVP, CAO, Fin | S - Sale | $55.58 | -1,892 | 29.4K | -6% | -$105.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-17 | S | D | 405 | $56.26 | 28,975 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2026-03-17 | S | D | 1,487 | $55.39 | 29,380 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $54.98 to $55.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |